Tecnoloxía para a monitorización e control de Diabetes

TECHNIQUES AND DEVICES PROVIDING ADAPTIVITY AND PERSONALIZATION IN DIABETES TREATMENT

Resumen de: EP4657456A2

Disclosed are a device, system, methods and computer-readable medium products that provide an updated insulin-to-carbohydrate ratio and an updated total daily insulin. The described processes may be used for periodic updating of the insulin-to-carbohydrate ratio and the total daily insulin. The insulin-to-carbohydrate ratio and/or the total may be used in the calculation of new doses of insulin that a drug delivery device may be commanded to deliver to a user.

CONTINUOUS BLOOD GLUCOSE MEASUREMENT APPARATUS

Resumen de: EP4656127A2

The present invention relates to a continuous blood glucose measurement apparatus which, by manufacturing a body-attachable unit in an assembled state inside an applicator, minimizes the additional work by a user for attaching the body-attachable unit to the body and thus enables the body-attachable unit to be attached to the body simply by means of operating the applicator, and, by providing a wireless communication chip on the body-attachable unit and enabling communication with an external terminal, can be used in a simple and convenient manner without the additional work of connecting a separate transmitter and enables easier maintenance and management, and, by having the operation of the body-attachable unit initiated by means of the user's manipulation after being attached to the body, enables the operation initiation point to be adjusted to an appropriate point as necessary by the user, enables an operation initiation in a stabilized state and thus enables more accurate blood glucose measurement.

A device for non-invasive analyte measurement

Resumen de: GB2641380A

An apparatus 2 for non-invasive in vivo measurement by Raman spectroscopy of analyte presence and/or concentration, such as glucose, in the skin of a subject is provided. The apparatus comprises a planar probe 8 having one or more optical sources (151, Fig. 1C) for irradiating a sample; a spectrometer 4 configured to receive Raman scattered radiation collected from the sample; a numerical aperture controller to determine the numerical aperture of the apparatus, and thereby control the input light received by the spectrometer. The numerical aperture controller may comprise an aperture stop (14, Fig 2A) within the spectrometer. The numerical aperture controller may be part of the probe for example a light absorbing region (25, Fig. 2C) around an opening in the PCB layer for receiving a Raman signal. Alternatively, the numerical aperture of an optical fibre interface (36, Fig. 5C) or buried light guide (54, Fig. 6B) may be selected; or the combination of a micro lens array (68, Fig. 7A) and pinhole array (64, Fig. 7B) in the probe may be selected to determine the numerical aperture.

METHOD OF PROVIDING NOTIFICATION OF SIGNAL LOSS IN GLUCOSE MONITORING SYSTEM

Resumen de: EP4656125A1

One embodiment may provide a method of providing a notification of signal loss in a glucose monitoring system, the method including, when a communication failure occurs between a terminal and a sensor transmitter, delaying a signal loss notification for a first period of time by the terminal, when the communication failure persists for the first period of time, further determining whether signal loss persists for a second period of time by the terminal, when the signal loss persists for the second period of time, generating the signal loss notification by the terminal, and outputting, by the terminal, the signal loss notification to a user.

METHOD OF OUTPUTTNG BLOOD GLUCOSE DATA

Resumen de: EP4657457A1

One embodiment may provide a method of outputting blood glucose data including obtaining biometric information in response to an advertisement transmitted by a sensor transmitter, generating the biometric information as output, in the case that a communication failure occurs, indicating a data gap during a period of the communication failure, and if the communication failure is resolved, filling the data gap during a period from a time point when the communication failure is resolved to one advertisement which arrives after the communication failure is resolved.

BODY ATTACHMENT UNIT FOR CONTINUOUS GLUCOSE MONITORING

Resumen de: EP4656133A2

The present invention relates to a body attachment unit for continuous glucose monitoring. The present invention provides a body attachment unit for continuous glucose monitoring, wherein: the body attachment unit is manufactured in the state in which the body attachment unit is assembled in an applicator, and thus separate additional work is minimized and the body attachment unit can be attached to the body by simply operating the applicator; in particular, a wireless communication chip is disposed in the body attachment unit so as to communicate with an external terminal, and thus simple and convenient use can be achieved without any additional work for connection of a separate transmitter and maintenance and management can also be easily performed; and the monitoring operation is started by a user's manipulation after the body attachment unit is attached to the body, and thus the user can adjust the operation start time to an appropriate point as necessary and the operation can be started in a stabilized state so as to enable more accurate glucose monitoring.

Continuous glucose measurement apparatus

Resumen de: NZ803295A

Prior art glucose measurement devices have issues relating to poor user experiences where manual multiple steps are required to obtain readings. Herein described is a glucose measurement apparatus, comprising a plunger body (300) disposed inside the main case and configured to move the body attachable unit from a first location to a second location, a needle unit (550) separably coupled to the body attachable unit, a return prevention unit (340, 161) configured to block returning movement of the plunger body to the first position after the plunger body is moved to the second position is included in the main case, and the needle unit (550) is configured to move together with the body attachable unitas the body attachable unit being moved from the first location to the second location, and is configured to move toward the first location after the body attachable unit is inserted into the body.

BIOMETRIC SENSORS FOR ENHANCED DETECTION, STIMULATION, AND NOTIFICATION

Resumen de: US2025359828A1

The technologies discussed herein relate to a biometrics system comprising one or more processors, computer storage memory having computer-executable instructions, surgically implantable devices, and wearables (e.g., an apparel item configured for an upper torso, an apparel item configured for a lower torso, a sock, a headband, other types of wearables, or one or more combinations thereof) having one or more biometric sensors (e.g., a heart rate sensor, a sweat sensor, a glucose sensor, other types of biometric sensors, or one or more combinations thereof) and one or more sensation devices (e.g., a plurality of visible light sources, a haptic feedback device, other types of sensation devices, or one or more combinations thereof). The wearables may also include one or more environmental sensors. The wearables emulate, transmogrify, or enhance one or more human senses using the one or more sensation devices based on biometric data or environmental data received.

CATHETER INSERTION DEVICE AND METHOD OF INSERTING A CATHETER

Resumen de: US2025360273A1

An insulin infusion system is provided with a manual insertion device having a dual retraction spring (230) configuration for automatic introducer needle (222) retraction. A button (200) of the insertion device is used to insert the introducer needle (222) and catheter (202), and once the introducer needle (222) and catheter (202) have been fully inserted, a rotating engagement releases the dual retraction springs (230) such that the introducer needle (222) automatically retracts, leaving the catheter (202) in the body of the user. An end of the introducer needle (222) remains in the inserted catheter (202) and/or in the septum (206) of the inserted catheter (202) to provide an uninterrupted fluid path.

NON-INVASIVE GLUCOSE MEASUREMENT DEVICE AND METHOD

Resumen de: WO2025244151A1

The present invention relates to a non-invasive glucose measurement device and method. To this end, the non-invasive glucose measurement device according to one embodiment of the present invention may comprise: a light irradiation unit which is positioned beneath an inner lower case disposed beneath an inserted finger, and which includes a first light-emitting element and a second light-emitting element for irradiating light toward the finger placed on the inner lower case; a light reception unit which is disposed on an inner upper case disposed on the finger, and which includes a first light-receiving element and a second light-receiving element for receiving the light irradiated from the light irradiation unit and transmitted through the finger; a motor unit including a first motor disposed at one side of the inner lower case and a second motor disposed at the other side of the inner lower case; a pressure sensor unit which is disposed beneath the inner lower case, and which includes a first pressure sensor and a second pressure sensor for measuring pressure applied by the finger; and a processor for measuring glucose by using the amount of light received through the light reception unit.

METHODS, SYSTEMS, AND DEVICES FOR CALIBRATION AND OPTIMIZATION OF GLUCOSE SENSORS AND SENSOR OUTPUT

Resumen de: US2025359790A1

A continuous glucose monitoring system may utilize externally sourced information regarding the physiological state and ambient environment of its user for externally calibrating sensor glucose measurements. Externally sourced factory calibration information may be utilized, where the information is generated by comparing metrics obtained from the data used to generate the sensor's glucose sensing algorithm to similar data obtained from each batch of sensors to be used with the algorithm in the future. The output sensor glucose value of a glucose sensor may also be estimated by analytically optimizing input sensor signals to accurately correct for changes in sensitivity, run-in time, glucose current dips, and other variable sensor wear effects. Correction actors, fusion algorithms, EIS, and advanced ASICs may be used to implement the foregoing, thereby achieving the goal of improved accuracy and reliability without the need for blood-glucose calibration, and providing a calibration-free, or near calibration-free, sensor.

BLOOD GLUCOSE ESTIMATION USING NEAR INFRARED LIGHT EMITTING DIODES

Resumen de: US2025359762A1

Near Infrared Spectroscopy is employed to non-invasively detect blood glucose concentrations, in a multi-sensing detection device. A multi-layered artificial neural network is used to assess these relationships of non-linear interference from human tissue, as well as differences among individuals, and accurately estimate blood glucose levels. Diffuse reflectance spectrum from the palm at six different wavelengths analyzed with a neural network, results in a correlation coefficient as high as 0.9216 when compared to a standard electrochemical glucose analysis test.

COMPUTERIZED METHOD AND SYSTEM FOR DETERMINING AN EXERCISE-RELATED INDEX FOR AN EXERCISING HUMAN USER

Resumen de: US2025364143A1

A method for determination of an event-related index for a human user, where:one provides time-based data for an observation period, with:time-based blood glucose data for the totality of the observation period, said time-based blood glucose data being derived from a continuous glucose monitor,time-based event data for the event period,a computerized index determination module determines said event-related index as a composite index of the blood glucose data related to the event period and the blood glucose data outside the event period.

METHODS OF TREATING DIABETES

Resumen de: ZA202305438B

Described herein are fixed doses and dosing regimens for long-acting insulin receptor agonists suitable for once-weekly dosing, such as weekly basal insulin-Fc (BIF).

SAFETY INSULIN PEN NEEDLE

Resumen de: EP4653033A1

Provided is a safety insulin pen needle. The safety insulin pen needle includes a needle hub, a protective sleeve, a needle cap, and a limiting block. A fixed post protruding along with an injection needle is disposed on the needle hub. A snap-fit step is disposed on the surface of the fixed post. The injection needle is inserted through the protective sleeve. A spring is clamped between the protective sleeve and the needle hub such that the protective sleeve is axially movable relative to the needle hub to expose or cover a needle tip of the injection needle. A protruding edge is disposed on an outer wall of the protective sleeve. A first limiting step and a second limiting step are disposed on an inner wall of the protective sleeve along a direction in which the injection needle penetrates. The inner diameter of the second limiting step is smaller than the inner diameter of the first limiting step. The needle cap is fixedly assembled with the needle hub and encloses the protective sleeve within the needle cap. The needle cap is provided with a through-hole allowing the protective sleeve to extend out. The through-hole limits the protruding edge. The limiting block is located in an inner cavity of the protective sleeve and is sleeved on the injection needle. A first end of the limiting block is provided with a claw that engages with the snap-fit step, and a second end of the limiting block cooperates with the first limiting step or the second limiting step to stop the protec

SENSOR APPLICATOR ASSEMBLY FOR CONTINUOUS GLUCOSE MONITORING SYSTEM

Resumen de: AU2025223826A1

A sensor applicator assembly for a continuous glucose monitoring system is provided. The sensor applicator assembly is assembled as a single unitary product in which a sensor module measuring a blood glucose level is preinstalled in an applicator, such that the sensor module is ejected by an operation of the applicator to be attached to a human body. The applicator includes a main container and a plunger body fixedly coupled to a first position within the main container. The plunger body is configured to be decoupled from the first position and to be moved to a second position in an injecting direction. The sensor module is coupled to one end portion of the plunger body to be moved integrally with the plunger body as the plunger body being moved toward the second position. An adhesive layer is attached to a lower surface of the sensor module to attach the sensor module to the human body, and is configured to be moved together with the sensor module as the plunger body being moved toward the second position. A sensor applicator assembly for a continuous glucose monitoring system is provided. The sensor applicator assembly is assembled as a single unitary product in which a sensor module measuring a blood glucose level is preinstalled in an applicator, such that the sensor module is ejected by an operation of the applicator to be attached to a human body. The applicator includes a main container and a plunger body fixedly coupled to a first position within the main container. T

COMPOSITIONS AND METHODS FOR TREATING POSTURAL TACHYCARDIA SYNDROME

Resumen de: US2025353905A1

The present invention provides compositions and methods for treating Postural orthostatic tachycardia syndrome (POTS). In some embodiments, the POTS is associated with hypermobility spectrum disorders/hypermobile Ehlers-Danlos syndrome (HSD/hEDS). In various embodiments, the invention relates to administering a composition comprising an effective amount of a molecular antagonist of Glucose-dependent Insulinotropic Polpeptide (GIP) to a patient in need thereof. In various embodiments, the molecular antagonist can be provided in a form for convenient self-administration upon the onset of symptoms or to prevent or reduce postprandial POTS symptoms, or in other embodiments, is administered at a set frequency.

Apparatus for Optimizing A Patient's Insulin Dosage Regimen

Resumen de: US2025356983A1

An apparatus for optimizing a patient's insulin dosage regimen over time, comprising: at least a first computer-readable memory for storing data inputs corresponding at least to one or more components in a patient's present insulin dosage regimen and the patient's blood-glucose-level measurements determined at a plurality of times; a processor operatively connected to the at least first computer-readable memory, the processor programmed at least to determine from the data inputs corresponding to the patient's blood-glucose-level measurements determined at a plurality of times whether and by how much to vary at least one of the one or more components of the patient's present insulin dosage regimen in order to maintain the patient's future blood-glucose-level measurements within a predefined range; and a display operative to display information corresponding to at least the patient's present insulin dosage regimen.

System, device and method of dynamic glucose profile response to physiological parameters

Resumen de: AU2025259998A1

Method, device and system for providing consistent and reliable glucose response information to physiological changes and/or activities is provided to improve glycemic control and health management. Method, device and system for providing consistent and reliable glucose response information to physiological changes and/or activities is provided to improve glycemic control and health management. ov o v

NON-INVASIVE MONITORING SYSTEM

Resumen de: AU2025259892A1

(57) Abstract: A wearable device for non-invasive monitoring of the presence, amount, and/or concentration of an analyte in a sample from a user of the device is described. The analyte is selected to be indicative of or related to a physiological status of a user. Relevant physiological status include hypoglycemia, infection, respiratory infection, urinary infection, gastrointestinal infection, obesity, diabetes, type I diabetes and type II diabetes. (57) Abstract: A wearable device for non-invasive monitoring of the presence, amount, and/or concentration of an analyte in a sample from a user of the device is described. The analyte is selected to be indicative of or related to a physiological status of a user. Relevant physiological status include hypoglycemia, infection, respiratory infection, urinary infection, gastrointestinal infection, obesity, diabetes, type I diabetes and type II diabetes. ct c t

MODELING TARGETS OF CONTINUOUS GLUCOSE MONITORING METRICS FOR GLYCEMIC CONTROL

Resumen de: US2025352092A1

Disclosed herein are techniques for blood glucose management. In one example, a processor-implemented method includes receiving an input of a target value of a first continuous glucose monitoring (CGM) metric, estimating a target value of at least a second CGM metric that corresponds to the target value of the first CGM metric, and providing the estimated target value of at least the second CGM metric to a user. In some examples, the processor-implemented method also includes determining that the estimated target value of at least the second CGM metric meets a predetermined criterion, and configuring an insulin delivery system based on the target value of the first CGM metric.

SYSTEMS AND METHODS FOR CONTINUOUS GLUCOSE MONITORING OUTCOME PREDICTIONS

Resumen de: AU2024252061A1

Methods and devices include predicting future glucose and engagement levels for a user by receiving the user's glucose levels collected by a continuous glucose monitoring (CGM) device over a time period, receiving engagement data associated with the user, wherein the engagement data are associated with the user's medication intake, diet, physical activity, laboratory results, and education activity, determining a first glycemia risk index (GRI) value, determining, using a machine learning model and responsive to the user's glucose levels and the engagement data collected over the time period, one or more predictions for future glucose levels for the user including a prediction that a future GRI value is greater than or less than the first GRI value, and determining, using the machine learning model and responsive to the user's engagement data collected over the time period, one or more predictions for future engagement levels.

HOUSING FOR AN INTEGRATED GLUCOSE MONITORING SYSTEM

Resumen de: US2025352094A1

An integrated glucose monitoring system comprising a glucometer and mobile device housed in a housing. The glucometer includes a measurement component to receive a blood glucose test strip containing a sample of blood of an individual, and a port to transmit the blood glucose measurement to a mobile device. The mobile device communicatively and physically coupled to the glucometer. The mobile device includes a port configured to couple with the glucometer, a communication component to receive the blood glucose measurement from glucometer, a power management component to transmit power to the glucometer, and another port to receive power from a power source to power the mobile device. The housing is to house the glucometer and the mobile device to form a single solitary glucose monitoring system.

NEUROMODULATION TO TARGET GLUCOSE TRANSPORTER AND/OR INCRETIN PATHWAYS

Resumen de: US2025352127A1

The subject matter of the present disclosure generally relates to techniques for neuromodulation that include applying energy (e.g., ultrasound energy) into the tissue to cause a change in a glucose transporter pathway molecule and/or an incretin pathway molecule. In one embodiment, the neuromodulation is performed as a treatment of a metabolic disorder.

BLOOD GLUCOSE LEVEL MEASUREMENT DEVICE AND BLOOD GLUCOSE LEVEL MEASUREMENT METHOD

Nº publicación: WO2025239063A1 20/11/2025

Solicitante:

HAMAMATSU PHOTONICS K K [JP]
\u6D5C\u677E\u30DB\u30C8\u30CB\u30AF\u30B9\u682A\u5F0F\u4F1A\u793E

Resumen de: WO2025239063A1

This blood glucose level measurement device comprises: a light output unit that outputs light; a light detection unit that detects light that has been output by the light output unit and passed through a living body; a temporal phase difference calculation unit that, on the basis of the detection result of the light detection unit, calculates the temporal phase difference between an oxygenated hemoglobin waveform pertaining to the oxygenated hemoglobin concentration of the blood of the living body and a deoxygenated hemoglobin waveform pertaining to the deoxygenated hemoglobin concentration of the blood of the living body; a blood glucose level calculation unit that calculates the blood glucose level of the living body on the basis of the calculated temporal phase difference; a level of similarity estimation unit that estimates the level of waveform similarity between the oxygenated hemoglobin waveform and the deoxygenated hemoglobin waveform; and a reliability estimation unit that estimates the reliability of the calculated blood glucose level. The reliability estimation unit estimates that the reliability becomes smaller as the level of waveform similarity becomes smaller.